ZEN-3365

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameZEN-3365
Drug Alias NameZEN-003365ZEN-3365
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain and extra terminal domain protein inhibitors
TargetsBromodomain and extra terminal domain protein
Therapy Area/IndicationsLymphoproliferative DisordersLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesZenith Epigenetics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesZenith Epigenetics
Active IndicationsN/A
Inactive IndicationsLymphoproliferative DisordersLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A